- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Dr. Smith's Diaper Rash Ointment
- CVS Caremark to stop selling tobacco in all store locations
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PORT WASHINGTON, N.Y. — A subsidiary of Aceto Corp. has launched two generic drugs for treating infectious diseases, the company said Monday.
Aceto said its Rising Pharmaceuticals subsidiary launched flucytosine capsules, a version of Valeant Pharmaceuticals International's Ancobon, used to treat serious infections; and chloroquine phosphate tablets, a generic version of Sanofi's malaria drug Aralen. The drugs' branded versions had sales of $20 million during the 12-month period ended in June, Aceto said.
"The chloroquine phosphate launch marks the first leveraging of a product by Rising that was brought to them directly as a result of Aceto's worldwide sourcing capabilities," Aceto chairman and CEO Albert Eilender said. "This illustrates the synergistic business opportunities we believe will become more plentiful as we move forward."